Clorox Company (CLX) 12-Month Stock Forecast & Price Target Cone

Per the Roarable RQD rating, CLX scores 66 out of 100, earning a C+ grade and the verdict "Roarable Hold — Upper Neutral / Watch for Breakout." The five pillars are: Fundamental Cash Engine at 15/20 (ROIC 37.2%; FCF yield 7.1%), Whale 13F Flow at 10/20 (institutional accumulation and options positioning), Insider Conviction at 18/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 10/20 (Beta 0.93; sector sensitivity), and Forensic Balance Sheet at 13/20 (Altman Z 2.93; Piotroski F 7/9; Debt/Equity 0.85). For a prospective investor, the strongest pillar is insider conviction, which the rating treats as a cluster-flow signal, while the weakest pillars are institutional flow and macro fit, which carry half-weight. The cash engine and balance sheet pillars support the stock's durability, but the rating's upside case depends on whether institutional positioning improves; the verdict language ("Watch for Breakout") indicates the rating sees the stock as near neutral rather than clearly positioned for upside. Valuation tradeoffs are visible in the market data: a 12.1x forward P/E and 5.61% dividend yield are set against a price that has traded between $79.12 and $128.9 over 52 weeks. A low beta of 0.93 suggests market-like sensitivity, so the rating's macro pillar reflects sector sensitivity rather than outsized volatility. These are analytical observations, not a personalized recommendation.

Clorox Company (The) is a NYSE-listed issuer classified under Consumer Discretionary, Specialty Chemicals per the SEC profile. Per the market data, the company reports a gross margin of 45.2%, operating margin of 14.2%, and net margin of 11.6%. Not available in source data for product lines, customer segments, or revenue mix. Not available in source data for detailed monetization model.

Per the SEC financials, revenue was broadly flat across the three periods, while operating income and net income rose meaningfully from FY 2023 to FY 2025. Per the market data, ROIC is 37.2% and net margin is 11.6%. Per the Roarable RQD rating, the Altman Z-Score is 2.93, the Piotroski F-Score is 7/9, and Debt/Equity is 0.85, which together describe a moderately healthy balance sheet. FCF declined from $825.5M in FY 2023 to $483.0M in FY 2024 before recovering to $761.0M in FY 2025.

Per the news wire, six items reference CLX. Headlines include a volatility-driven repurchase piece, a valuation and dividend-trap comparison against Colgate, a Seeking Alpha valuation note, and a MarketBeat report on a new institutional position. A TradingView item reports a 12-month price target cut to $93.94, implying 11% upside, and is the only item flagged RED under "RISK WATCH." The remaining items are flagged YELLOW under "MARKET WIRE." Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals.

Not available in source data for consensus rating, price targets, 13F holdings, or Form 4 transactions. The analyst data and holders sections are recorded as NONE. The only price-target reference is a news headline reporting a cut to $93.94.

• What are the company's product lines and revenue mix, given the source profile describes only a sector and industry classification?
• Why are EPS values reported as N/A in all three financial periods when TTM EPS is listed at 6.81?
• What is the basis for the FY 2023 cash figure reported as N/A, and how does it affect the trend analysis?
• What institutional and insider transactions underlie the pillar scores, given the holders section is empty?
• What drove the reported operating income increase from FY 2023 to FY 2025 despite flat revenue?